KalVista Pharmaceuticals Inc’s recent filing unveils that its CHIEF MEDICAL OFFICER Audhya Paul K. unloaded Company’s shares for reported $24272.0 on May 23 ’25. In the deal valued at $11.31 per share,2,146 shares were sold. As a result of this transaction, Audhya Paul K. now holds 113,026 shares worth roughly $1.33 million.
Then, Yea Christopher sold 1,926 shares, generating $21,782 in total proceeds. Upon selling the shares at $11.31, the CHIEF DEVELOPMENT OFFICER now owns 98,189 shares.
Before that, Audhya Paul K. sold 2,689 shares. KalVista Pharmaceuticals Inc shares valued at $31,933 were divested by the CHIEF MEDICAL OFFICER at a price of $11.88 per share. As a result of the transaction, Audhya Paul K. now holds 110,172 shares, worth roughly $1.3 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Friday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock fall -0.76% to $11.80. Over the last five days, the stock has gained 3.33%. KalVista Pharmaceuticals Inc shares have risen nearly 39.32% since the year began. Nevertheless, the stocks have risen 6.50% over the past one year. While a 52-week high of $15.50 was reached on 04/30/25, a 52-week low of $7.30 was recorded on 01/13/25. SMA at 50 days reached $11.98, while 200 days put it at $10.89.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 11.54, which if violated will result in even more drops to 11.27. On the upside, there is a resistance level at 11.97. A further resistance level may holdings at 12.13. The Relative Strength Index (RSI) on the 14-day chart is 48.35, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 51.06%. Stochastics %K at 38.60% indicates the stock is a holding.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
